$TAC

TransAlta (NYSE:TAC) Stock Price Passes Above 200

TransAlta (NYSE:TAC) shares rose above their 200-day moving average on Monday, trading up to $13.82 and last at $13.5650. The 200-day average is $13.23. The article cites analyst actions including RBC and CIBC reiterating “outperform” and TD Securities “buy,” with MarketBeat showing a $21.33 consensus target. It also notes May 6 quarterly EPS of $0.04 vs $0.01 expected and a $0.07 quarterly dividend payable July 1.

Original reporting
Published May 26, 2026, 5:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 6:16 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TransAlta (NYSE:TAC) Stock Price Passes Above 200 — source image
Decision brief

The 30-second read

$TACBullishMed
01

Why it matters

Traders may treat the 200-day crossover as a momentum trigger while using the earnings beat and dividend timing as confirmation; watch for follow-through versus resistance near recent highs ($13.82).

02

Market read

Company-specific technical breakout plus earnings beat and dividend schedule create a constructive near-term setup for TAC, tempered by revenue miss and negative net margin.

03

What to watch

High leverage (debt-to-equity 6.61) and negative net margin (-9.46%) could increase downside risk if rates/credit conditions worsen, even with a dividend and EPS beat.

Relevance 8/10Timing: Immediate (technical level break) with fundamental reinforcement from the May 6 earnings print and upcoming July 1 dividend payment.

Background

The piece frames TransAlta’s move as both a technical trend change (200-day MA) and a near-term fundamental check-in (May 6 quarterly earnings and dividend disclosure).

Company-level read

Ticker impact

$TACBullishMedium confidence
Context

TransAlta shares crossed above the 200-day moving average and followed with an earnings beat (EPS $0.04 vs $0.01 consensus) plus a July 1 dividend record date.

Expected impact

Bias toward upward drift/mean-reversion higher while price holds above the 200-day level; upside may be capped by weaker revenue vs expectations and negative net margin.

Evidence & confidence

The article cites a specific technical trigger (cross above 200-day MA), a quantified earnings beat, and a concrete dividend schedule; however, revenue missed expectations and financial ratios (negative net margin) temper conviction.

Market effects

As a utility/power generator, TAC strength can modestly improve sentiment toward North American regulated/merchant power peers, though the article is company-specific.

Limited to Canadian/American investor sentiment for TransAlta given the dual listing reference (TSE:TA) and Calgary HQ context.

Low; no global macro or cross-border deal/regulatory catalyst is described.

Counterpoint

The stock’s technical strength may fade if the post-earnings revenue miss ($406.19M vs $436.36M) signals demand/price headwinds despite EPS outperformance.

Key entities

  • TransAlta Corporation

    Crossed above its 200-day moving average; reported EPS beat on May 6 and disclosed a July 1 dividend payment.

Related articles

$TACMedAI 8/10

Canadian Energy News, Top Headlines, Commentaries, Features & Events

TransAlta Corp said it will buy two natural gas peaking plants near Denver, Mountain Peak Power and Canyon Peak Power, from Blackstone for about $1 billion. The 318 MW assets are fully contracted for over 25 years. TransAlta will assume $750 million project debt and raise about $250 million equity via a C$350 million bought deal. Expected annual adjusted core profit is ~$80 million and free cash flow ~$33 million; deal closes early Q4 2026.

$TACMed

Across the Nutraverse: Probiotic foods in China, Akkermansia I.P., IM8’s $1bn financing deal

SAMR has drafted new China rules for probiotic health foods, open for consultation until Aug 24, 2026, including higher minimum CFU at shelf life and required strain details for traceability and quality. The Akkermansia Company received a new US patent covering marketing substantially purified Akkermansia for metabolic disorders, including live and pasteurized forms. IM8 secured $1bn growth financing from General Catalyst’s CVF to expand internationally.

$TACMed

The tab to keep a Northwest coal plant on standby keeps rising. Who will pay?

Utilities in the Pacific Northwest are contesting TransAlta’s request to recover costs for keeping its Centralia, Washington coal plant on standby under renewed Trump-era DOE emergency orders. TransAlta says its first April 30 invoice was nearly $20 million and estimates $23 million for repairs if standby extends into Q3–Q4 2026. FERC is reviewing opposition from utilities and grid operators.